1. Home
  2. CNS vs CPRX Comparison

CNS vs CPRX Comparison

Compare CNS & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Inc

CNS

Cohen & Steers Inc

HOLD

Current Price

$74.75

Market Cap

3.7B

Sector

Finance

ML Signal

HOLD

Logo Catalyst Pharmaceuticals Inc.

CPRX

Catalyst Pharmaceuticals Inc.

HOLD

Current Price

$31.40

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNS
CPRX
Founded
1986
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.4B
IPO Year
2004
2006

Fundamental Metrics

Financial Performance
Metric
CNS
CPRX
Price
$74.75
$31.40
Analyst Decision
Hold
Strong Buy
Analyst Count
2
1
Target Price
$71.50
$35.00
AVG Volume (30 Days)
200.1K
1.7M
Earning Date
04-16-2026
05-11-2026
Dividend Yield
3.96%
N/A
EPS Growth
N/A
28.24
EPS
0.82
0.50
Revenue
$427,536,000.00
$119,072,803.00
Revenue This Year
$4.71
$9.20
Revenue Next Year
$4.37
$10.51
P/E Ratio
$91.01
$62.77
Revenue Growth
4.07
16.39
52 Week Low
$58.39
$19.05
52 Week High
$78.81
$32.56

Technical Indicators

Market Signals
Indicator
CNS
CPRX
Relative Strength Index (RSI) 56.66 71.94
Support Level $59.88 $31.25
Resistance Level $78.69 $32.56
Average True Range (ATR) 2.05 0.04
MACD 0.02 -0.14
Stochastic Oscillator 64.29 86.67

Price Performance

Historical Comparison
CNS
CPRX

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two-thirds of its $98.4 billion in managed assets at the end of February. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (25%) of its managed assets (base management fees) from institutional clients, 48% (55%) from open-end funds, and 13% (20%) from closed-end funds.

About CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Share on Social Networks: